Cure8 trial brief
Real-world registry data on upadacitinib can help patients and clinicians understand how the drug performs outside clinical trials, including patterns of use, effectiveness, and safety over time.
Adults with moderate-to-severe UC or Crohn's disease on or considering upadacitinib; gastroenterologists and clinical researchers studying JAK inhibitors and real-world IBD outcomes.
This is a ClinicalTrials.gov registry record for a non-interventional, observational study in Belgium enrolling adults with moderate-to-severe ulcerative colitis or Crohn's disease who are prescribed upadacitinib in routine care.
About 280 participants will be followed for up to three years to collect real-world data on effectiveness and safety; primary outcomes include patient-reported clinical remission measures up to ~52 weeks.
The study will enroll participants who started commercially prescribed upadacitinib at least 12 months prior to inclusion or who are initiating treatment as part of routine care; participants previously treated with upadacitinib in a trial or early-access program are excluded.
Visits align with regular clinical practice and the protocol states no additional burden is expected beyond routine care.
This is a trial registry (observational) record without posted results. Observational studies report associations and real-world experience but are not randomized controlled trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
